Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Investors Lab
  • Published:

Any diamonds in the diagnostic coal?

Nature Biotechnology volume 24, page 930 (2006)Cite this article

Although you might have been led to believe there is a 'clear vision' for the molecular diagnostics revolution, in reality the investing picture is much murkier. Revenues haven't produced much profit or free cash flow (and are unlikely to do so anytime soon). And rather than stand-alone diagnostics makers or drug companies with diagnostics divisions making good investments, it is clinical testing and medical technology (medtech) companies that are most likely going to turn out winners.

False starts

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Tom Jacobs is cofounder of Complete Growth Investor, http://www.completegrowth.com/, a stock service for individual investors. Tom owned no shares of the companies mentioned here at time of writing.

    • Tom Jacobs
Authors
  1. Tom Jacobs
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, T. Any diamonds in the diagnostic coal?. Nat Biotechnol 24, 930 (2006). https://doi.org/10.1038/nbt0806-930

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0806-930

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing